has been demonstrated in both prohypertrophic and antihypertrophic settings, although the reasons for such discrepant results are not well understood. We determined how AMPK is regulated in response to phenylephrine-induced cardiomyocyte hypertrophy and assessed whether AMPK activity may be a factor underlying the antihypertrophic effect of adenosine receptor agonists. The role of AMPK in hypertrophic responses was determined by assessing the effect of the AMPK activator 5-aminoimidazole-4-carboxyamide ribonucleoside on three hypertrophic indexes, including protein synthesis, cell surface area, and fetal gene expression. The changes in phosphorylation of the catalytic ␣-subunit of AMPK at two different sites, Thr 172 and Ser 485/491 , in response to phenylephrine and adenosine receptor agonists were also examined. 5-Aminoimidazole-4-carboxyamide ribonucleoside completely abolished phenylephrine-induced increases in protein synthesis, cell surface area, and fetal gene expression. AMPK phosphorylation time course studies revealed that phenylephrine induced a time-dependent activation at site Ser 485/491 , in contrast to adenosine receptor agonists, which demonstrated rapid AMPK phosphorylation at Thr 172 . Furthermore, the phosphorylation at Ser 485/491 by phenylephrine was not affected by the addition of adenosine receptor agonists, although, conversely, phosphorylation of AMPK at Thr 172 by adenosine receptor agonists was abrogated by the addition of phenylephrine. We propose from these results that cardiomyocyte hypertrophic and antihypertrophic responses, at least with respect to inhibition of phenylephrine-induced hypertrophy by adenosine receptor agonists, are mediated by multisite AMPK regulation. The latter are reflected by increased phosphorylation at Ser 485/491 and at Thr 172 , associated with prohypertrophic and antihypertrophic responses, respectively. neonatal ventricular myocytes; hypertrophy; adenosine 5=-monophosphate-activated protein kinase phosphorylation ALTHOUGH ADENOSINE HAS BEEN implicated in attenuating cardiac hypertrophy, the precise mechanism by which the nucleoside mediates its antihypertrophic actions has yet to be fully elucidated. Previously, our laboratory has demonstrated that the activation of adenosine receptor subtypes A 1 , A 2a , and A 3 with specific agonists inhibited phenylephrine-induced cardiomyocyte hypertrophy, which appears to be unrelated to inhibition of phenylephrine-induced MAPK activation (11). Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a regulator of fatty acid oxidation and glucose uptake in the heart and skeletal muscle in response to altered energy supply and/or demand (reviewed in Ref. 8). AMPK regulates energy metabolism by phosphorylation of key enzymes involved in metabolic pathways, including acetyl-coenzyme A carboxylase and mammalian target of rapamycin by modulating their activities and by regulating the activity of transcription factors and transcriptional cofactors (2). There is emerging evidence for a role of AMPK in the regulation of cardiac hypertrophic growth (1, 4, 22, 29) , although AMPK activation has been demonstrated in both prohypertrophic and antihypertrophic settings (3, 4, 22, 29) . For example, mutations in the ␥ 2 -subunit of AMPK have been reported to lead to familial hypertrophic cardiomyopathy (3). Also, significant elevations in ␣ 1 -and ␣ 2 -AMPK activity and a twofold increase in ␣ 1 -AMPK expression have been reported in rat hearts with pressure overload hypertrophy (29). Although these studies suggest that AMPK is an essential component of the hypertrophic response, activation of AMPK has also been shown to inhibit protein synthesis that is associated with cardiomyocyte hypertrophy through a mechanism involving eukaryotic elongation factor 2 kinase and p70S6 kinase pathways (4). Furthermore, a reduction in AMPK signaling has been shown to lead to exacerbation of heart failure (22).
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The reason for the apparent contrasting roles for AMPK in cardiomyocyte hypertrophy is not known, but may involve complex mechanisms underlying AMPK regulation. In this regard, AMPK is a heterotrimeric serine/threonine protein kinase, consisting of a catalytic ␣-subunit and two regulatory ␤-and ␥-subunits (30, 31) . The ␣-subunit contains a threonine phosphorylation site (Thr 172 ), the major regulatory phosphorylation site of AMPK that plays a critical role in regulating AMPK activity (30, 31) . Furthermore, AMPK contains other phosphorylation sites on the ␣-subunit, including Ser 485/491 (30, 31) . Activation of AMPK occurs under conditions where there are increases in the intracellular concentration of AMP, which allosterically activates AMPK by binding to its ␥-subunit and promoting phosphorylation of Thr 172 by upstream kinases (30, 31) , although it has also been proposed that AMP activates AMPK by also protecting Thr 172 from dephosphorylation (27) . Furthermore, AMPK can be phosphorylated through AMP-independent pathways during stimulation with metformin or 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR), which, when taken into cells, is converted to an AMP analog and which has been extensively used in studies for inducing the activation of AMPK (4) .
In view of the complexities of AMPK regulation, it is possible that multiple residues on AMPK are phosphorylated and that the role of AMPK in physiological or pathophysio-logical regulation is dependent on the resultant sum of these multiple phosphorylations. Indeed, it has been hypothesized that AMPK activation may play dual roles in the development of cardiac hypertrophy, i.e., activation of AMPK during early hypertrophy may be antihypertrophic, whereas activation of AMPK during sustained hypertrophy may be prohypertrophic (9) . Accordingly, the aim of this study was to understand how AMPK is regulated in response to phenylephrine-induced cardiomyocyte hypertrophy and to determine the nature of this regulation under conditions of adenosine receptor activation when the hypertrophic effect is blunted. In particular, we sought to determine whether AMPK is regulated through dual mechanisms mediated by multisite phosphorylations.
MATERIALS AND METHODS
Primary culture of neonatal ventricular myocytes. Primary ventricular myocyte cultures were prepared from 1-to 4-day-old SpragueDawley pups (Charles River, St. Constant, Quebec, Canada), as previously described (11) . The studies reported here have been approved by the Animal Use Subcommittee of the University of Western Ontario, and procedures conform to the guidelines of the Canadian Council on Animal Care (Ottawa, ON, Canada). Rats were decapitated, and the ventricles were washed, cut, and subsequently digested with a series of treatments with 0.1% collagenase II. The reaction was terminated with the addition of fetal bovine serum. The cellular extracts were filtered and centrifuged at 2,000 rpm for 5 min. The supernatant was then aspirated, and the resulting pellet was resuspended in cell culture medium. To remove nonmyocardial cells, a differential attachment procedure was used. The suspended cell mixture underwent two rounds of attachment via preplating in Primeria T-75 culture flasks at 37°C for 30 and 90 min, respectively. During this time, noncardiomyocytes (fibroblasts, endothelial cells, and smooth muscle cells) attach, while a majority of the myocytes remain in suspension. The final myocyte preparation was plated on Primeria-coated tissue culture dishes in cell culture. Myocytes were maintained in medium for 24 h before all experiments. Examination of neonatal cardiomyocytes by light microscopy revealed that cultures were confluent and myocytes were beating.
Cardiomyocyte treatment. The effect of 10 M phenylephrine (SigmaAldrich, Oakville, ON, Canada), AICAR (Cell Signaling, Beverly, MA), as well as the A 1-receptor 
on the phosphorylation of the catalytic ␣-subunit of AMPK at Thr 172 and Ser 485/491 was determined by treating myocytes with these agents for 0, 5, 10, 15, 30, or 60 min. Some experiments were also done to determine the effect of the nonspecific adenosine receptor agonist 2-chloroadenosine (10 M), the metabolically stable analog of adenosine on AMPK phosphorylation. All adenosine agonists were purchased from Sigma-Aldrich. Additional studies were done to determine the effects of adenosine receptor activation on phenylephrine-stimulated AMPK phosphorylation. For this purpose, cells were pretreated with the respective adenosine receptor agonists for 30 min before the addition of phenylephrine for a further 10 min, which represented the peak phenylephrine-induced stimulation of AMPK-␣ (Ser 485/491 ) phosphorylation. Cardiomyocyte surface area analysis. Cardiomyocytes were plated at a concentration of 1 ϫ 10 6 cells/plate to obtain individually attached cells. Cardiomyocytes were visualized through a Leica inverted microscope equipped with a Polaroid digital camera at ϫ20 magnification. Cardiomyocyte surface area was measured using Mocha software (SPPS, Chicago, IL) from 50 randomly selected cells per experiment and averaged to give an N value of 1.
RNA isolation, reverse transcription, and real-time polymerase chain reaction analysis of ANP and ␣-skeletal actin. Total RNA was isolated by the TRIzol method, according to the manufacturer's instructions (Invitrogen, Carlsbad, CA) from cardiomyocytes that were plated at a density of 6 ϫ 10 6 cells/plate. A total of 2 g of RNA were used to synthesize single-stranded cDNA by Superscript II H-Reversetranscriptase, according to the manufacturer's instructions (Invitrogen). The cDNA was diluted 10-fold, and 1 l of diluted cDNA was used in a 20-l polymerase chain reaction (PCR) reaction. Gene expression analysis was performed with SYBRgreen jumpstart Taq ready mix DNA polymerase (Invitrogen), and the fluorescence was measured and quantified by DNA engine Opticon II (MJ Research, Waltham, MA). The following primers were used: 5=-GTAACCCGTTGAACCCCATT-3= (forward) and 5=-CCATCCAATCGGTAGTA GCG-3= (reverse) for 18s rRNA, 5=-CACGGCATTATCACCAACTG-3= (forward) and 5=-CCGGAGGCATAGAGAGACAG-3= (reverse) for ␣-skeletal actin, and 5=-CTGCTA GACCACCTGGAGGA-3= (forward) and 5=-AAGCTGT-TGCAGCCTAGTCC-3= (reverse) for ANP. The PCR conditions and cycle numbers were optimized for each gene. PCR conditions for amplification of all genes were 30s at 94°C, followed by annealing at 20s for 18s rRNA at 55°C, 25s for ␣-skeletal actin at 60°C, 25s for ANP at 59°C, and elongation at 72°C for 30s. ANP and ␣-skeletal actin were amplified for 40 cycles, and 18s rRNA was amplified for 35 cycles. Melting curve analysis showed a single product formation for each gene amplified. Gene expression was normalized with 18s as an internal control.
Determination of protein synthesis by [ 3 H]leucine incorporation.
Cardiomyocytes were plated into a 24-well plate at a concentration of 4 ϫ 10 5 cells/well. After serum-starvation for 24 h, 2 Ci [ 3 H]leucine were added, which was immediately followed by the appropriate treatments. At the end of the incubation, labeling was discontinued by three washings with ice cold phosphate-buffered saline and 30-min incubation with 5% trichloroacetic acid on ice to precipitate proteins. Afterwards, cells were further washed twice with ice cold 5% trichloroacetic acid and lysed in 0.5 N NaOH overnight. The cell mixture was neutralized with the addition of 0.5 N HCl and added to liquid scintillation fluid before counting of incorporated radioactivity.
SDS-PAGE and Western blotting. Cardiomyocytes plated at a density of 6 ϫ 10 6 cells/plate were harvested in 100 l of lysis buffer, and total protein was quantified by a Bradford Protein Assay Kit (Bio-Rad Laboratories, Mississauga, Ontario, Canada). A total of 40 g of protein was loaded onto 10% SDS-PAGE, separated at 100 V for 2 h, and transferred overnight at 50 V onto 45 M nitrocellulose membranes. Membranes underwent Ponceau S (Bio-Rad Laboratories) staining to verify transfer efficiency and then were washed before blocking for 1 h with 5% dry skim milk. Membranes were probed with antibodies directed against phospho-AMPK-␣ Thr172 , phospho-AMPK-␣1 Ser485 / ␣2 Ser491 , phospho-acetyl CoA carboxylase, AMPK, total and phospho-AKT (all from Cell Signaling Technology, Danvers, MA), and actin (Millipore, Billerica, MA), all at a dilution of 1:1,000 for 1 h. Following incubations with the primary antibody, membranes underwent incubations with the secondary antibody for 1 h, and proteins were detected using ECL reagent.
Statistical analysis. Results are given as means Ϯ SE. Statistical significance was determined by using a one-way ANOVA, and post hoc comparisons were performed by the method of Student-NewmanKeuls. Differences were considered significant when P Ͻ 0.05.
RESULTS

AICAR attenuates phenylephrine-induced cardiomyocyte hypertrophy.
The mechanism by which adenosine receptor activation negatively regulates phenylephrine-induced cardiomyocyte hypertrophy remains unclear. To assess the possible role of AMPK, we determined the effect of AICAR on phenylephrine-induced hypertrophy, as determined by cell surface area, [ presence of AICAR. As summarized in Fig. 1 , cells treated with phenylephrine exhibited cardiomyocyte hypertrophy, as evidenced by increased cell surface area (B), [ 3 H]leucine incorporation (C), and increased gene expression of ANP (D) and ␣-skeletal actin (E). Although AICAR on its own was without effect on any parameter, it completely abrogated phenylephrine-induced hypertrophy, as assessed by all markers. Examples of myocytes after various treatments are shown in micrographs in Fig. 1A .
Adenosine receptor agonists increase AMPK-␣ phosphorylation selectively at Thr 172 . The ability of the AMPK activator AICAR to inhibit phenylephrine-induced hypertrophy suggests an involvement of AMPK as an endogenous antihypertrophic factor. We next sought to determine whether adenosine receptor stimulation can activate AMPK by treating cardiomyocytes with the A 1 -receptor agonist CPA, the A 2a -receptor agonist CGS 21680, the A 3 -receptor agonist IB-MECA, or the nonspecific adenosine receptor agonist 2-chloroadenosine for 0 -60 min. Lysates derived from adenosine agonist-treated cardiomyocytes were first analyzed by phospho-specific AMPK-␣ Thr 172 immunoblotting (Fig. 2) . Western blotting analysis revealed that all three specific adenosine receptor agonists, as well as 2-chloroadenosine, induced a rapid transient increase in AMPK-␣ phosphorylation at Thr 172 , which peaked at 5 min (P Ͻ 0.05), after which values were not significantly different from control (Fig. 2) . We also investigated whether adenosine agonists increased phosphorylation of AMPK at alternative amino acids using antibodies recognizing phosphorylation at Ser 485/491 . However, as shown in Fig. 3 , immunoblot analysis revealed that none of the adenosine agonists exerted any significant effect on phosphorylation of AMPK-␣ 1 /␣ 2 at Ser 485/491 . In addition to demonstrating that adenosine receptor agonists increase AMPK phosphorylation, we also determined the effect of these agents on AMPK activity, as demonstrated by phosphorylation of acetyl-CoA carboxylase. As shown in Fig. 4 (Fig. 5B) , in contrast to results observed with adenosine receptor agonists (Fig. 2) . Maximal phosphorylation of AMPK at Ser 485/491 was observed after 10 min of phenylephrine treatment (P Ͻ 0.05), which then decreased in a time-dependent manner. Taken together, these experiments demonstrate opposite sites for AMPK phosphorylation associated with the antihypertrophic effects of adenosine 
Increased phosphorylation of AMPK-␣ Thr
172 by adenosine receptor agonists is blunted by phenylephrine. AMPK phosphorylation profiles were also determined in phenylephrinetreated cardiomyocytes pretreated with adenosine receptor agonists to evaluate the relationship between the two AMPK-␣ phosphorylation sites. As shown in Fig, 6A , the ability of phenylephrine to increase phosphorylation of AMPK-␣ 1 /␣ 2 at Ser 485/491 was not affected by pretreatment with adenosine receptor agonists (Fig. 6A) . Interestingly, however, pretreatment with phenylephrine before administration of adenosine receptor agonists tended to decrease adenosine agonist-induced increases in phosphorylation of AMPK-␣ at Thr 172 with significant inhibition against both CPA and IB-MECA-induced AMPK Thr172 phosphorylation (Fig. 6B) , although values remained significantly greater from control. However, pretreatment with phenylephrine had no effect on AMPK phosphorylation at Thr 172 produced by 2-chloroadenosine (Fig. 6B) . was assessed in cardiomyocytes treated with AICAR for 0 -60 min, followed by Western blotting analysis of AMPK phosphorylation. As shown in Fig. 7A , AICAR selectively increased phosphorylation of AMPK at Thr 172 , with no effect on the phosphorylation of AMPK-␣ 1 /␣ 2 at Ser 485/491 (Fig. 7B) . Maximum phosphorylation at Thr 172 occurred at 60 min following AICAR addition, thus demonstrating a markedly different phosphorylation profile than that observed with adenosine receptor agonists (Fig. 3) . Because of evidence that AMPK modulates the activity of other kinases including Akt (PKB) (28a), we examined whether AICAR exerts any effect on this kinase. As shown in Fig. 7C , AICAR increased levels of phospho-Akt, with significant effects seen throughout most of the AICAR treatment period. The effect of AICAR on AMPK phosphorylation was mimicked by metformin (2 mM), which is also known to inhibit phenylephrine-induced cardiomyocyte hypertrophy via AMPK activation (4) . In this regard, metformin maximally increased AMPK Thr172 phosphorylation by 71 Ϯ 11% (P Ͻ 0.05, n ϭ 8) without affecting phosphorylation at Ser 485/491 .
AICAR increases phosphorylation of AMPK-␣ exclusively at
DISCUSSION
The major goal of this study was to identify the nature of the regulation of AMPK and its possible contribution to both the hypertrophic effect of phenylephrine and the antihypertrophic effect of adenosine receptor activation. We have demonstrated that AICAR, an AMPK activator, prevented the induction of ANP and ␣-skeletal actin mRNA expression and attenuated the increases in both protein synthesis and cell surface area associated with phenylephrine-induced cardiomyocyte hypertrophy. We have also demonstrated dual mechanisms regulating AMPK activity during cardiomyocyte hypertrophy. Specifically, we have shown that the antihypertrophic effect of adenosine receptor agonists is associated with phosphorylation of AMPK-␣ at Thr 172 , the major regulatory site, which also resulted in increased AMPK activity, as determined by increased levels of phosphorylated acetyl-CoA carboxylase. Furthermore, we demonstrated that the prohypertrophic influence of phenylephrine was associated with phosphorylation of AMPK-␣ 1 /␣ 2 at Ser 485/491 . The nature of AMPK involvement in regulating the hypertrophic program remains unclear. Accordingly, we first investigated the effect of AICAR on phenylephrine-induced hypertrophy. The ability of AICAR to attenuate phenylephrine-induced hypertrophy suggests an antihypertrophic effect of AMPK and complements the findings of Li et al. (20) , who demonstrated that AICAR inhibits hypertrophy in rats subjected to aortic coarctation, possibly by inhibiting the calcineurin-nuclear factor of activated T cell pathway. However, it is possible that AMPK plays multifaceted roles, especially in view of the fact that AMPK can be regulated, not only by changes in the cellular AMP-to-ATP ratio, but also by extracellular ligands (18) . Thr 172 of the ␣-subunit of AMPK is the major regulatory site that, once phosphorylated, significantly increases activity of AMPK. The possibility that the antihypertrophic effect of AICAR is not mediated solely or specifically by increased AMPK phosphorylation at Thr 172 cannot also not be ruled out, since AICAR also increased Akt phosphorylation in cardiomyocytes, which could be secondary to AMPK activation (28a). However, the precise role of Akt in mediating the antihypertrophic effect of AICAR, or indeed, adenosine receptor activation, requires further studies, especially as the relationship between AMPK and Akt in cardiovascular tissues appears to be extremely complex (reviewed in Ref. 9a) .
The present report is the first to demonstrate the ability of adenosine receptor activation to increase AMPK phosphorylation at Thr 172 , which was associated with an antihypertrophic effect of these receptor agonists. Thus it appears that activation of multiple adenosine receptor subtypes (A 1 , A 2a , and A 3 ) increases AMPK phosphorylation at Thr 172 . Although this does not prove a cause-and-effect relationship, the results suggest that increased phosphorylation of AMPK-␣ at Thr 172 may account, at least in part, for the antihypertrophic effect of adenosine receptor agonists, a concept bolstered by the ability of AICAR to stimulate AMPK Thr172 phosphorylation, which was also associated with an antihypertrophic influence. However, it is important to note that the profiles of AMPK Thr172 phosphorylation produced by adenosine receptor agonists and AICAR differed substantially, with the former producing a transient, early, and modest increase in phosphorylation (Fig.  2) , whereas AICAR-induced increases in AMPK Thr172 phosphorylation occurred later, was more robust, and was sustained for the remainder of the 60-min treatment period (Fig. 3) . This finding suggests different mechanism underlying the ability of these agents to increase AMPK phosphorylation. Although the precise nature of these differences cannot be stated with certainty at this time, it should be noted that AICAR does not directly activate AMPK, but must be first taken up by the cell via an adenosine transport system and converted into the ribotide, 5-aminoimidazole-4-carboxamide-ribotide via phosphorylation by adenosine kinase (7). Second, 5-aminoimidazole-4-carboxamide-ribotide must bind the AMPK-␥-subunit, thus inducing a conformation change in AMPK, which allows for the phosphorylation of its catalytic ␣-subunit by upstream kinases and the conversion of AMPK into its activated state (34) . As such, this may reflect the basis for the delayed and sustained response to AICAR in terms of AMPK Thr172 phosphorylation.
Although phosphorylation at Thr 172 is likely the major regulator of AMPK activity, additional sites on AMPK may also be targets for phosphorylation. Indeed, there was no effect of phenylephrine on phosphorylation of AMPK at Thr 172 , although it significantly increased phosphorylation of AMPK-␣ 1 /␣ 2 Ser 485/491 , where adenosine receptor agonists produced no effect. Thus the prohypertrophic effect of phenylephrine was associated with selective phosphorylation of AMPK at Ser 485/491 . It is interesting to note, however, that, to date, regulation of AMPK-␣ 1 /␣ 2 Ser 485/491 phosphorylation during the hypertrophic response has not been well characterized.
Indeed, site-directed mutagenesis studies have demonstrated that the major site of phosphorylation of AMPK occurs on Thr 172 , which is reflective of the overall activity level of the enzyme and which suggests that other phosphorylation sites such as Ser 485/491 are not required for the proper function of AMPK activity (30, 31) . It has also been suggested that increases in phosphorylation at Ser 485/491 could be due to an autophosphorylation phenomenon (14) . Although AICAR induces AMPK activation by binding to AMPK and promoting the phosphorylation of Thr 172 by the upstream kinases LKB1 (22) or CaMKK-␤ (13), how phenylephrine induces phosphorylation of AMPK at Ser 485/491 is not known. However, it has been suggested that phosphorylation of AMPK at this site is mediated by intracellular messengers, including protein kinase B/Akt (28) or protein kinase A (19) .
Our study also found that phenylephrine can attenuate adenosine agonist-induced phosphorylation of AMPK-␣ at Thr 172 , although this was seen only with individual receptor agonists, but not with respect to 2-chloroadenosine when multiple receptors would be expected to be stimulated, suggesting that multiple adenosine receptor activation can overcome the inhibitory effect of phenylephrine on AMPK phosphorylation at Thr 172 . Whether the ability of phenylephrine to blunt the effect of individual adenosine receptor agonist is due to prior phosphorylation of AMPK-␣ 1 /␣ 2 at Ser 485/491 is presently uncertain. However, in agreement with this possibility, it has been demonstrated that phosphorylation of AMPK-␣ 1 /␣ 2 Ser 485/491 is associated with blunted LKB1-induced phosphorylation of AMPK-␣ at Thr 172 in isolated hearts and cultured cardiomyocytes (14, 28) . Irrespective of the exact mechanisms, the modest ability of phenylephrine pretreatment to blunt adenosine-induced AMPK-␣ phosphorylation at Thr 172 may explain the efficacy of adenosine receptor agonists to act as potent antihypertrophic factors. Fig. 8 . Potential proposed mechanism of the dual pathways leading to AMPK-␣ phosphorylation and their relationship to cardiomyocyte hypertrophy (described in DISCUSSION). AR, adrenergic receptor; R, receptor.
